Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
β-Catenin (D10A8) XP® Rabbit mAb 8480 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry Chromatin Immunoprecipitation
H M R Mk 92 Rabbit IgG
Phospho-β-Catenin (Ser33/37/Thr41) Antibody 9561 40 µl
Western Blotting
H M R Mk 92 Rabbit 
Phospho-β-Catenin (Thr41/Ser45) Antibody 9565 40 µl
Western Blotting
H M Mk 92 Rabbit 
Phospho-β-Catenin (Ser552) (D8E11) Rabbit mAb 5651 40 µl
Western Blotting Immunoprecipitation
H M 92 Rabbit IgG
Phospho-β-Catenin (Ser675) (D2F1) XP® Rabbit mAb 4176 40 µl
Western Blotting Immunoprecipitation Immunofluorescence
H 92 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
Western Blotting
Goat 

Product Description

The β-Catenin Antibody Sampler Kit provides an economical means of detecting total β-catenin as well as β-catenin phosphorlylated at various residues. The kit contains enough primary and secondary antibody to perform four Western blots with each antibody.


Specificity / Sensitivity

Each antibody in this kit recognizes only its specific target and does not cross-react with other family members.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser33, Ser37 and Thr41 of human β-catenin or residues surrounding Thr41 and Ser45 of human β-catenin. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro714 of human β-catenin protein, a synthetic phosphopeptide corresponding to residues surrounding Ser552 of human β-catenin protein, or a synthetic phosphopeptide corresponding to residues surrounding Ser675 of human β-catenin.

β-Catenin is a key downstream effector in the Wnt signaling pathway (1). It is implicated in two major biological processes in vertebrates: early embryonic development (2) and tumorigenesis (3). CK1 phosphorylates β-catenin at Ser45. This phosphorylation event primes β-catenin for subsequent phosphorylation by GSK-3β (4-6). GSK-3β destabilizes β-catenin by phosphorylating it at Ser33, Ser37, and Thr41 (7). Mutations at these sites result in the stabilization of β-catenin protein levels and have been found in many tumor cell lines (8).


Both Akt and PKA were shown to phosphorylate β-catenin at Ser552 and Ser675. Phosphorylation at Ser552 and Ser675 induces β-catenin accumulation in the nucleus and increases its transcriptional activity (9-12).


1.  Cadigan, K.M. and Nusse, R. (1997) Genes Dev 11, 3286-305.

2.  Wodarz, A. and Nusse, R. (1998) Annu Rev Cell Dev Biol 14, 59-88.

3.  Polakis, P. (1999) Curr Opin Genet Dev 9, 15-21.

4.  Amit, S. et al. (2002) Genes Dev 16, 1066-76.

5.  Liu, C. et al. (2002) Cell 108, 837-47.

6.  Yanagawa, S. et al. (2002) EMBO J 21, 1733-42.

7.  Yost, C. et al. (1996) Genes Dev 10, 1443-54.

8.  Morin, P.J. et al. (1997) Science 275, 1787-90.

9.  Fang D et al. (2007) J Biol Chem 282, 11221–9

10.  Hino S et al. (2005) Mol Cell Biol 25, 9063–72

11.  Taurin, S. et al. (2006) J Biol Chem 281, 9971-9976.

12.  He, X.C. et al. (2007) Nat Genet 39, 189-198.


Entrez-Gene Id 1499
Swiss-Prot Acc. P35222

Protein Specific References

Wang Z et al. (2003) Cancer Res 63, 5234–5

Lévy L et al. (2004) Mol Cell Biol 24, 3404–14

Hino S et al. (2005) Mol Cell Biol 25, 9063–72

Winer IS et al. (2006) J Biol Chem 281, 26181–7

Fang D et al. (2007) J Biol Chem 282, 11221–9

Arai T et al. (2008) Cell Cycle 7, 3556–63

Ge X et al. (2009) Mol Biol Cell 20, 419–27

Du C et al. (2009) Cancer Res 69, 1117–24

Hadjihannas MV et al. (2010) EMBO Rep 11, 317–24

Palka-Hamblin HL et al. (2010) J Cell Sci 123, 236–45

Omori E et al. (2011) Oncogene 30, 3336–44

Rey O et al. (2012) J Biol Chem 287, 1158–67

Li Y et al. (2012) Biochim Biophys Acta 1823, 465–75

Chocarro-Calvo A et al. (2013) Mol Cell 49, 474–86

Wang Z et al. (2003) Cancer Res 63, 5234–5

Lévy L et al. (2004) Mol Cell Biol 24, 3404–14

Hino S et al. (2005) Mol Cell Biol 25, 9063–72

Winer IS et al. (2006) J Biol Chem 281, 26181–7

Fang D et al. (2007) J Biol Chem 282, 11221–9

Arai T et al. (2008) Cell Cycle 7, 3556–63

Ge X et al. (2009) Mol Biol Cell 20, 419–27

Du C et al. (2009) Cancer Res 69, 1117–24

Hadjihannas MV et al. (2010) EMBO Rep 11, 317–24

Palka-Hamblin HL et al. (2010) J Cell Sci 123, 236–45

Omori E et al. (2011) Oncogene 30, 3336–44

Rey O et al. (2012) J Biol Chem 287, 1158–67

Li Y et al. (2012) Biochim Biophys Acta 1823, 465–75

Chocarro-Calvo A et al. (2013) Mol Cell 49, 474–86

Wang Z et al. (2003) Cancer Res 63, 5234–5

Lévy L et al. (2004) Mol Cell Biol 24, 3404–14

Hino S et al. (2005) Mol Cell Biol 25, 9063–72

Winer IS et al. (2006) J Biol Chem 281, 26181–7

Fang D et al. (2007) J Biol Chem 282, 11221–9

Arai T et al. (2008) Cell Cycle 7, 3556–63

Ge X et al. (2009) Mol Biol Cell 20, 419–27

Du C et al. (2009) Cancer Res 69, 1117–24

Hadjihannas MV et al. (2010) EMBO Rep 11, 317–24

Palka-Hamblin HL et al. (2010) J Cell Sci 123, 236–45

Omori E et al. (2011) Oncogene 30, 3336–44

Rey O et al. (2012) J Biol Chem 287, 1158–67

Li Y et al. (2012) Biochim Biophys Acta 1823, 465–75

Chocarro-Calvo A et al. (2013) Mol Cell 49, 474–86

Wang Z et al. (2003) Cancer Res 63, 5234–5

Lévy L et al. (2004) Mol Cell Biol 24, 3404–14

Hino S et al. (2005) Mol Cell Biol 25, 9063–72

Winer IS et al. (2006) J Biol Chem 281, 26181–7

Fang D et al. (2007) J Biol Chem 282, 11221–9

Arai T et al. (2008) Cell Cycle 7, 3556–63

Ge X et al. (2009) Mol Biol Cell 20, 419–27

Du C et al. (2009) Cancer Res 69, 1117–24

Hadjihannas MV et al. (2010) EMBO Rep 11, 317–24

Palka-Hamblin HL et al. (2010) J Cell Sci 123, 236–45

Omori E et al. (2011) Oncogene 30, 3336–44

Rey O et al. (2012) J Biol Chem 287, 1158–67

Li Y et al. (2012) Biochim Biophys Acta 1823, 465–75

Chocarro-Calvo A et al. (2013) Mol Cell 49, 474–86

Wang Z et al. (2003) Cancer Res 63, 5234–5

Lévy L et al. (2004) Mol Cell Biol 24, 3404–14

Hino S et al. (2005) Mol Cell Biol 25, 9063–72

Winer IS et al. (2006) J Biol Chem 281, 26181–7

Fang D et al. (2007) J Biol Chem 282, 11221–9

Arai T et al. (2008) Cell Cycle 7, 3556–63

Ge X et al. (2009) Mol Biol Cell 20, 419–27

Du C et al. (2009) Cancer Res 69, 1117–24

Hadjihannas MV et al. (2010) EMBO Rep 11, 317–24

Palka-Hamblin HL et al. (2010) J Cell Sci 123, 236–45

Omori E et al. (2011) Oncogene 30, 3336–44

Rey O et al. (2012) J Biol Chem 287, 1158–67

Li Y et al. (2012) Biochim Biophys Acta 1823, 465–75

Chocarro-Calvo A et al. (2013) Mol Cell 49, 474–86


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

2951
β-Catenin Antibody Sampler Kit